Phase Ib, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Patients With Pulmonary Hypertension and HFpEF
Latest Information Update: 19 Aug 2025
At a glance
- Drugs HS 235 (Primary)
- Indications Heart failure; Pulmonary hypertension
- Focus Adverse reactions
- Sponsors 35Pharma
Most Recent Events
- 19 Aug 2025 New trial record